InnoGene Co

InnoGene Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of InnoGene Co (344860.KQ) as of Oct 15, 2026 is 3.59 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 7.13 % — a change of -49.60% (lower).

EBIT/Assets

3.59 %

YoY

-49.60%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of InnoGene Co is 2024 3.59 % . Operating Income to Assets Ratio (EBIT/Assets) of InnoGene Co was 2023 7.13 % . It decreases by -49.60% lower compared to the previous year.

The InnoGene Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
0.85 KRW
Jan 1, 2019
-5.75 KRW
Jan 1, 2020
25.63 KRW
Jan 1, 2021
35.97 KRW
Jan 1, 2022
18.71 KRW
Jan 1, 2023
7.13 KRW
Jan 1, 2024
3.59 KRW
The InnoGene Co EBIT/Assets history
YEAREBIT/AssetsYoY
3.59 %-49.60%
7.13 %-61.90%
18.71 %-47.98%
35.97 %+40.37%
25.63 %-545.36%
-5.75 %-776.28%
0.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InnoGene Co Stock analysis

What does InnoGene Co do? InnoGene Co Ltd is a company based in Seoul, South Korea, operating within the Consumer Staples sector and the Consumer products industry. The company has 77 employees and went public on April 27, 2020. Its website is http://www.innogene.com/. InnoGene focuses on research and development related to skin regeneration and anti-aging solutions, utilizing stem cell technology and fusion technology. The company develops and manufactures cosmetics aimed at skin regeneration and aging control. Additionally, InnoGene is involved in the manufacturing and distribution of medical devices. The company's primary activities revolve around creating products that address skin health and aging concerns, leveraging scientific research in stem cell applications. As a publicly traded entity, InnoGene operates under the ticker symbol 344860.KQ and is registered with the ISIN KR7344860002. The company's headquarters are located in Seoul, and it serves a market that values innovative skincare and medical device solutions. InnoGene's product portfolio includes both cosmetic and medical device offerings, targeting consumers interested in advanced skincare technologies. The company's operations are centered on research-driven development to enhance skin health and combat aging effects. InnoGene Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InnoGene Co stock

Operating Income to Assets Ratio (EBIT/Assets) of InnoGene Co is 3.59 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of InnoGene Co changed from 7.13 % to 3.59 %, representing a -49.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) InnoGene Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s InnoGene Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — InnoGene Co

All Key Metrics — InnoGene Co